These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26289547)

  • 81. Ethical issues in tuberculosis diagnosis and treatment.
    Selgelid MJ; Reichman LB
    Int J Tuberc Lung Dis; 2011 Jun; 15 Suppl 2():9-13. PubMed ID: 21740653
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Procurement and Supply Management System for MDR-TB in Nigeria: Are the Early Warning Targets for Drug Stock Outs and Over Stock of Drugs Being Achieved?
    Jatau B; Avong Y; Ogundahunsi O; Shah S; Tayler Smith K; Van den Bergh R; Zachariah R; van Griensven J; Ekong E; Dakum P
    PLoS One; 2015; 10(6):e0128500. PubMed ID: 26098673
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Programmatic versus personalised approaches to managing the global epidemic of multidrug-resistant tuberculosis.
    Chakaya JM; Marais B; du Cros P; Ntoumi F; Mfinanga S; Kapata N; Hasnain SE; Nathavitharana R; Zumla A
    Lancet Respir Med; 2020 Apr; 8(4):334-335. PubMed ID: 32113573
    [No Abstract]   [Full Text] [Related]  

  • 84. Drug-resistant tuberculosis in Africa.
    Mwinga A
    Ann N Y Acad Sci; 2001 Dec; 953():106-12. PubMed ID: 11795401
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Association between diabetes mellitus and multi-drug-resistant tuberculosis: a protocol for a systematic review and meta-analysis.
    Tegegne BS; Habtewold TD; Mengesha MM; Burgerhof JG
    Syst Rev; 2017 Jan; 6(1):6. PubMed ID: 28088237
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.
    Kendall EA; Fofana MO; Dowdy DW
    Lancet Respir Med; 2015 Dec; 3(12):963-72. PubMed ID: 26597127
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Tackling the MDR-TB epidemic in Ukraine: every little helps … and much more needed.
    Burman M; Nikolayevskyy V; Kontsevaya I; Molina-Moya B; Rzhepishevska O; Guglielmetti L
    J Public Health (Oxf); 2018 Mar; 40(1):210-211. PubMed ID: 28334761
    [No Abstract]   [Full Text] [Related]  

  • 88. Multidrug-resistant tuberculosis treatment programmes insufficiently consider comorbid mental disorders.
    Walker IF; Baral SC; Wei X; Huque R; Khan A; Walley J; Newell JN; Elsey H
    Int J Tuberc Lung Dis; 2017 Jun; 21(6):603-609. PubMed ID: 28482954
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications.
    Husain AA; Kupz A; Kashyap RS
    Epidemiol Health; 2021; 43():e2021022. PubMed ID: 33831293
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The global tuberculosis situation and the inexorable rise of drug-resistant disease.
    Marais BJ
    Adv Drug Deliv Rev; 2016 Jul; 102():3-9. PubMed ID: 26855302
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Multidrug-resistant tuberculosis.
    Seaworth BJ
    Infect Dis Clin North Am; 2002 Mar; 16(1):73-105. PubMed ID: 11917817
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Multi-sectoral approach to DOTS--the only hope.
    Kibuga D
    Scand J Infect Dis; 2001; 33(10):725-7. PubMed ID: 11728034
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tuberculosis a re-emerging disease.
    De Lorenzo S; Tiberi S
    Intern Emerg Med; 2012 Oct; 7 Suppl 3():S185-7. PubMed ID: 23073855
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Linking surveillance with action against drug-resistant tuberculosis.
    Cohen T; Manjourides J; Hedt-Gauthier B
    Am J Respir Crit Care Med; 2012 Sep; 186(5):399-401. PubMed ID: 22592806
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study.
    Cohen T; Colijn C; Finklea B; Wright A; Zignol M; Pym A; Murray M
    PLoS One; 2008 Jun; 3(6):e2363. PubMed ID: 18523659
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Challenges in estimating the total burden of drug-resistant tuberculosis.
    Cohen T; Colijn C; Wright A; Zignol M; Pym A; Murray M
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1302-6. PubMed ID: 18369201
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Double Standards in Global Health: Medicine, Human Rights Law and Multidrug-Resistant TB Treatment Policy.
    Nicholson T; Admay C; Shakow A; Keshavjee S
    Health Hum Rights; 2016 Jun; 18(1):85-102. PubMed ID: 27781001
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The political and ethical challenge of multi-drug resistant tuberculosis.
    Degeling C; Mayes C; Lipworth W; Kerridge I; Upshur R
    J Bioeth Inq; 2015 Mar; 12(1):107-13. PubMed ID: 25630591
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Tuberculosis--a missed opportunity?
    White VL
    Clin Med (Lond); 2002; 2(1):55-8. PubMed ID: 11873766
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Health care gaps in the global burden of drug-resistant tuberculosis.
    Cox V; Cox H; Pai M; Stillo J; Citro B; Brigden G
    Int J Tuberc Lung Dis; 2019 Feb; 23(2):125-135. PubMed ID: 30808447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.